Vaxcyte to Present at 2021 Cantor Virtual Global Healthcare Conference

Rhea-AI Summary

On September 21, 2021, Vaxcyte, Inc. (Nasdaq: PCVX) announced its participation in the 2021 Cantor Virtual Global Healthcare Conference. This event will take place on September 28, 2021, at 8:40 AM ET. A live webcast will be available on the company's website, with a replay accessible for 30 days post-conference. Vaxcyte is focused on developing advanced vaccines against common infectious diseases, with its lead candidate, VAX-24, targeting invasive pneumococcal disease.

FOSTER CITY, Calif., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced that Company management will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 8:40am ET.

A live webcast of the presentation can be accessed through the Investors & Media section of the Company’s website at http://investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference.

About Vaxcyte
Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, comprising the XpressCF™ platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte’s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. Vaxcyte’s lead vaccine candidate, VAX-24, is a preclinical, 24-valent broad-spectrum pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease. Vaxcyte’s pipeline also includes VAX-XP, a PCV with an expanded breadth of coverage of at least 30 strains; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; and VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease by targeting the keystone pathogen responsible for this chronic, oral inflammatory disease. For more information, visit www.vaxcyte.com.

Contacts:
Andrew Guggenhime, President and Chief Financial Officer
Vaxcyte, Inc.
650-837-0111
investors@vaxcyte.com

Janet Graesser, Vice President, Corporate Communications and Investor Relations
Vaxcyte, Inc.
917-685-8799
media@vaxcyte.com

FAQ

When will Vaxcyte participate in the Cantor Virtual Global Healthcare Conference?

Vaxcyte will participate in the conference on September 28, 2021, at 8:40 AM ET.

How can I watch Vaxcyte's presentation at the Cantor Conference?

You can watch the live webcast of Vaxcyte's presentation on their website under the Investors & Media section.

What is Vaxcyte's lead vaccine candidate?

Vaxcyte's lead vaccine candidate is VAX-24, which is aimed at preventing invasive pneumococcal disease.

What platform does Vaxcyte use for vaccine development?

Vaxcyte utilizes a cell-free protein synthesis platform, specifically the XpressCF™ platform.

How long will the webcast of Vaxcyte's presentation be available?

The replay of the webcast will be available for approximately 30 days after the conference.